Product Description
Mechanisms of Action: RNA polymerase Inhibitor,NN Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Hepatitis C, Chronic|Communicable Diseases|Hepatitis A
Phase 1: Hepatitis C, Chronic|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ANNAPURNA | P2 |
Completed |
Hepatitis C, Chronic |
2013-11-28 |
|
| ANNAPURNA | P2 |
Completed |
Hepatitis C, Chronic |
2013-11-01 |
|
| NP28302 | P2 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2013-05-01 |
|
| NP28326 | P1 |
Completed |
Healthy Volunteers |
2013-05-01 |